Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 in Moderate-to-Severe Chronic Spontaneous Urticaria
NCT06396026Phase 3Active, not recruiting
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing TLL-018 with Placebo to TLL-018 (2 arms). Primary endpoints: Urticaria Activity Score over 7 days at 12 weeks and Itch Severity Score over 7 days at 12 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
girocitinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06396026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396026.